Mesoblast Limited (NASDAQ:MESO, ASX:MSB)))), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration's (FDA) Office of Therapeutic
Nexcella, Inc. ("Nexcella", "Company", "We" or "Us"), a biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other
NeoGames (NASDAQ: NGMS) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $(0.13) by 269.23 percent. This is a 257.14 percent increase over losses of $(0.14) per share from the same period last year.
We want to be very clear about what our position has always been: Walgreens plans to dispense Mifepristone in any jurisdiction where it is legally permissible to do so. Once we are certified by the FDA, we will dispense
